GLPwatch

Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.

J Diabetes · 2019

Last updated 2026-05-28

Between 2009 and 2015 in northern Denmark, 57% of patients starting liraglutide took it as part of a combination therapy not originally approved. Most patients (73%) had health conditions that would have excluded them from the clinical trials used to approve liraglutide, and most also had other health issues or diabetes-related complications.

AI summary of the abstract below.

JournalJ Diabetes, 2019
Citations3
Relative citation ratio0.12
NIH percentile9
Molecules liraglutide
Conditions studied Type 2 Diabetes

Abstract

Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

Verbatim abstract via PubMed 30893522 ↗

Related research